



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Samidorphan-d₅

Cat. No.:	HY-123689S1
Molecular Formula:	C ₂₁ H ₂₁ D ₅ N ₂ O ₄
Molecular Weight:	375.47
Target:	Isotope-Labeled Compounds
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

Samidorphan-d₅ (ALKS-33-d₅) is a tritiated version of Samidorphan. Samidorphan is an orally active opioid system modulator that binds with high affinity to μ -opioid, κ -opioid, and δ -opioid receptors. Samidorphan is a μ -opioid receptor antagonist and a partial agonist at κ -opioid and δ -opioid receptors. Samidorphan acts primarily as an opioid receptor antagonist in vivo^{[1][2][3][4]}.

REFERENCES

- [1]. Russak, et al. Impact of deuterium substitution on the pharmacokinetics of pharmaceuticals. *Annals of Pharmacotherapy* 53.2 (2019): 211-236.
- [2]. McElroy SL, et al. A placebo-controlled pilot study of the novel opioid receptor antagonist ALKS-33 in binge eating disorder. *Int J Eat Disord*. 2013 Apr;46(3):239-45.
- [3]. Mark S. Todtenkopf, et al. Buprenorphine in Combination with Samidorphan (ALKS 33) Results in Antidepressive-Like Effects in Two Distinct Rat Models. *Eur Neuropsychopharmacol*. 2014;24a(Suppl 2):S366.
- [4]. Rehan ST, et al. Samidorphan/olanzapine combination therapy for schizophrenia: Efficacy, tolerance and adverse outcomes of regimen, evidence-based review of clinical trials. *Ann Med Surg (Lond)*. 2022 Jun 30;79:104115.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA